uniQure’s (QURE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of uniQure (NASDAQ:QURE) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $70.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for uniQure’s Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.43) EPS, FY2027 earnings at ($3.95) EPS, FY2028 earnings at ($3.19) EPS, FY2029 earnings at $0.21 EPS and FY2030 earnings at $4.19 EPS.

Several other equities research analysts have also recently weighed in on the company. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $15.00 to $60.00 in a report on Monday. Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Finally, Wolfe Research began coverage on shares of uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

uniQure Stock Down 3.5%

uniQure stock opened at $16.94 on Tuesday. The stock has a market cap of $1.06 billion, a PE ratio of -4.91 and a beta of 0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The stock’s fifty day moving average is $21.53 and its two-hundred day moving average is $29.49. uniQure has a 1-year low of $7.76 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The business had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. On average, sell-side analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Insider Activity

In other uniQure news, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the transaction, the chief financial officer owned 226,581 shares of the company’s stock, valued at $2,052,823.86. The trade was a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the sale, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 81,399 shares of company stock worth $1,527,645 over the last ninety days. 4.79% of the stock is owned by corporate insiders.

Institutional Trading of uniQure

Several institutional investors and hedge funds have recently bought and sold shares of QURE. Private Trust Co. NA acquired a new stake in uniQure during the 3rd quarter worth $28,000. Torren Management LLC acquired a new position in uniQure in the fourth quarter valued at $28,000. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc purchased a new stake in shares of uniQure in the fourth quarter valued at about $48,000. Finally, Smartleaf Asset Management LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $48,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Mizuho upgraded uniQure to “outperform” with a $35 price target (up from $12), and multiple firms (RBC, Wells Fargo, Chardan) issued bullish commentary or upgrades this week, supporting short-term buying interest. Mizuho upgrade / coverage roundup
• Positive Sentiment: Royal Bank of Canada and Wells Fargo raised ratings on QURE (coverage noted by AmericanBankingNews), which helped earlier session rallies and increased analyst attention ahead of key drug catalysts. RBC upgrade article
• Neutral Sentiment: Seeking Alpha published an analysis titled “A Unique Situation For UniQure” that dissects catalysts and risks; the piece may influence investors weighing upside vs. regulatory/legal risk but does not present new primary facts. A Unique Situation For UniQure
• Negative Sentiment: Hagens Berman highlighted reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” and “manipulated” data for the AMT-130 program — a serious regulatory credibility issue that increases the risk of further clinical/regulatory setbacks and fuels investor concern. Hagens Berman / FDA accusation alert
• Negative Sentiment: Multiple plaintiff law firms (Pomerantz, Bernstein Liebhard, Faruqi, Levi & Korsinsky, Rosen, Kahn Swick & Foti, ClaimsFiler) have filed or solicited investors in securities class actions and are publicizing April lead-plaintiff deadlines — raising potential litigation liability and ongoing headline risk. Pomerantz class action alert Bernstein Liebhard shareholder alert
• Negative Sentiment: HC Wainwright cut near- and multi-year earnings forecasts substantially (Q1–Q4 2026 and FY2026–FY2030 revisions), which signals weaker expected near-term financials and reduces forward EPS visibility despite the firm’s “Buy” rating — a factor pressuring valuation. HC Wainwright estimate revisions (MarketBeat summary)

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.